Arndt Vogel(@ArndtVogel) 's Twitter Profile Photo

Achievement of CR & Drug-Free Status by Atezo/Bev Combined with or without Curative Conversion in TACE-Unsuitable, Intermediate-Stage HCC
Gastroenterology | Karger
doi.org/10.1159/000529…
🔎 🇯🇵Proof-Of-Concept Study
👉Clinical/path. CR in 35% of pts!
😅the concept: 'curative conversion'…

Achievement of CR & Drug-Free Status by Atezo/Bev Combined with or without Curative Conversion in TACE-Unsuitable, Intermediate-Stage HCC
@GastroKarger 
doi.org/10.1159/000529…
🔎 🇯🇵Proof-Of-Concept Study
👉Clinical/path. CR in 35% of pts!
😅the concept: 'curative conversion'…
account_circle
Dott. Luigi Ruggiero(@DrLuigiRuggiero) 's Twitter Profile Photo

Nuova pubblicazione sugli effetti di tre giorni vs un giorno di dieta a basso residuo sulla qualità della preparazione intestinale per la colonscopia Gastroenterology | Karger

prepday prep preparation

Nuova pubblicazione sugli effetti di tre giorni vs un giorno di dieta a basso residuo sulla qualità della preparazione intestinale per la colonscopia @GastroKarger 

#endoscopy #colonscopy #bowel #bowelprepday #bowelprep #bowelpreparation #lowresiduediet #colonoscopy
account_circle
transplantid.net(@TransplantIDNet) 's Twitter Profile Photo

What are the newest recommendations from American Gastroenterological Association (AGA) regarding💩microbiota transplantation in the immunocompromised?

See their practice guidelines in Gastroenterology | Karger!

In the 'DRUGS AND THERAPIES'▶️'Fecal Microbiota Transplantation'📂

transplantid.net/2SHHJ2SK

What are the newest recommendations from @AmerGastroAssn regarding💩microbiota transplantation in the immunocompromised?

See their practice guidelines in @GastroKarger!

In the 'DRUGS AND THERAPIES'▶️'Fecal Microbiota Transplantation'📂

transplantid.net/2SHHJ2SK
account_circle
Arndt Vogel(@ArndtVogel) 's Twitter Profile Photo

Phase 1b Study of Lenvatinib + Pembrolizumab in HCC
Gastroenterology | Karger
doi.org/10.1159/000535…
🔎Extended Analysis of Study 116
👉ORR 43%; mDOR 17.1 mo
👉mPFS 9.3 mo, OS 20.4 mo
👉No treatment-emergent ADAs -> could be important in the future
ESMO - Eur. Oncology EASL Education ILCA

Phase 1b Study of Lenvatinib + Pembrolizumab in HCC
@GastroKarger
doi.org/10.1159/000535…
🔎Extended Analysis of Study 116
👉ORR 43%;  mDOR 17.1 mo
👉mPFS 9.3 mo,  OS 20.4 mo
👉No treatment-emergent ADAs -> could be important in the future
@myESMO @EASLedu @ILCAnews #livertwitter
account_circle
Gastroenterology | Karger(@GastroKarger) 's Twitter Profile Photo

As we embark on the journey of discovery and innovation in 2024, may it be a year filled with groundbreaking research and advancements in medical science. We wish all our followers a Happy New Year filled with new opportunities. Happy New Year! 🌟

🥂

account_circle
Federico Rossari(@f_rossari) 's Twitter Profile Photo

Big team effort and important achievement for the group! andrea casadei gardini and Margherita Rimini simply pivotal in orchestrating such a collaborative network 🙏
Check out our new paper in Gastroenterology | Karger ⬇️

account_circle
Simon Sirtl(@SimonSirtl) 's Twitter Profile Photo

Management of sinistral portal hypertension after pancreaticoduodenectomy | Out now in Digestive Diseases | Gastroenterology | Karger

karger.com/ddi/article/do…

account_circle